메뉴 건너뛰기




Volumn 22, Issue 1, 2001, Pages 75-76

Amantadine for dyskinesia in patients affected by severe Parkinson's disease

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BROMOCRIPTINE; CARBIDOPA; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; ROPINIROLE;

EID: 0034932441     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100720170054     Document Type: Conference Paper
Times cited : (52)

References (8)
  • 1
    • 0006647256 scopus 로고    scopus 로고
    • Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease
    • Verhagen M, Del Dotto P, van den Munckhof BS et al (1998) Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 50:1323-1326
    • (1998) Neurology , vol.50 , pp. 1323-1326
    • Verhagen, M.1    Del Dotto, P.2    Van Den Munckhof, B.S.3
  • 2
    • 0031868048 scopus 로고    scopus 로고
    • Acute delirium after withdrawal of amantadine in Parkinson's disease
    • Stewart A, Factor DO, Molho ES et al (1998) Acute delirium after withdrawal of amantadine in Parkinson's disease. Neurology 50:1456-1458
    • (1998) Neurology , vol.50 , pp. 1456-1458
    • Stewart, A.1    Factor, D.O.2    Molho, E.S.3
  • 3
    • 0029884473 scopus 로고    scopus 로고
    • Amantadine treatment is an independent predictor of improved survival in Parkinson's disease
    • Uitti RJ, Rajput AH, Ahlskog JE et al (1996) Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurology 46:1551-1556
    • (1996) Neurology , vol.46 , pp. 1551-1556
    • Uitti, R.J.1    Rajput, A.H.2    Ahlskog, J.E.3
  • 4
    • 0000224448 scopus 로고
    • Fahn S, Marsden CD, Calne DB, Goldstein M (eds) Macmillan Health Care Information, Florham Park
    • Fahn S, Elton R, Members of UPDRS Development Committee (1987) In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds) Recent developments in Parkinson's disease, vol. 2. Macmillan Health Care Information, Florham Park, pp 153-164
    • (1987) Recent Developments in Parkinson's Disease , vol.2 , pp. 153-164
    • Fahn, S.1    Elton, R.2
  • 5
    • 0028050082 scopus 로고
    • Utility of an objective dyskinesia rating scale for Parkinson's disease: Inter-and intrarater reliability assessment
    • Goetz CG, Stebbins GT, Shale HM et al (1994) Utility of an objective dyskinesia rating scale for Parkinson's disease: inter-and intrarater reliability assessment. Mov Disord 9:390-394
    • (1994) Mov Disord , vol.9 , pp. 390-394
    • Goetz, C.G.1    Stebbins, G.T.2    Shale, H.M.3
  • 6
    • 0002743072 scopus 로고
    • Anticholinergic drugs and amantadine in the treatment of Parkinson's disease
    • Calne DB (ed) Springer, Berlin Heidelberg New York
    • Lang AE, Blair RDG (1989) Anticholinergic drugs and amantadine in the treatment of Parkinson's disease. In: Calne DB (ed) Drugs for the treatment of Parkinson's disease. Springer, Berlin Heidelberg New York, pp 307-323
    • (1989) Drugs for the Treatment of Parkinson's Disease , pp. 307-323
    • Lang, A.E.1    Blair, R.D.G.2
  • 7
    • 0033999316 scopus 로고    scopus 로고
    • The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: A double blind, placebo-controlled study
    • Snow BJ, Macdonald L, Mcauley D et al (2000) The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double blind, placebo-controlled study. Clin Neuropharmacol 23:82-85
    • (2000) Clin Neuropharmacol , vol.23 , pp. 82-85
    • Snow, B.J.1    Macdonald, L.2    McAuley, D.3
  • 8
    • 0028873061 scopus 로고
    • Regional variations in the phamacology of NMDA receptor channel blockers: Implications for therapeutic potential
    • Porter RHP, Greenamyre JT (1995) Regional variations in the phamacology of NMDA receptor channel blockers: implications for therapeutic potential. J Neurochem 64:614-623
    • (1995) J Neurochem , vol.64 , pp. 614-623
    • Porter, R.H.P.1    Greenamyre, J.T.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.